Recessive dystrophic epidermolysis bullosa, also called RDEB, is one form of epidermolysis bullosa. Epidermolysis bullosa is a rare genetic condition that causes very fragile skin.

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a press release.With this approval, Zevaskyn (prademagene zamikeracel ...

The FDA has accepted for Priority Review the BLA for pz-cel (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa.

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa.

Patients with recessive dystrophic epidermolysis bullosa experienced a reduction in pain and itch with pregabalin treatment, according to small study. “Epidermolysis bullosa (EB) is a genetic ...

The global dystrophic epidermolysis bullosa market is driven by rising awareness, advances in early diagnosis, and improved treatment options.

The FDA approved the first treatment for dystrophic epidermolysis bullosa, a devastating condition that causes the skin to be extraordinarily fragile.

Recessive dystrophic epidermolysis bullosa (RDEB) is characterized by extensive blistering and severe skin wounds caused by a mutation in the COL7A1 gene.